US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

13.83

+1.209.50%

Pre-market: 13.70-0.1300-0.94%04:01 EDT

Volume:3.68M

Turnover:50.61M

Market Cap:1.09B

PE:6.81

High:14.19

Open:13.09

Low:13.01

Close:12.63

52wk High:17.29

52wk Low:5.70

Shares:78.65M

Float Shares:70.64M

Volume Ratio:2.42

T/O Rate:5.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):2.03

EPS(LYR):1.87

ROE:82.56%

ROA:2.29%

PB:4.69

PE(LYR):7.40

Loading ...

Overview Company News Filings

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Positioning Ivonescimab to Anchor a ~$200B PD-1xVEGF Market: Early NSCLC Validation and Commercial Head Start Support Buy Rating on Summit

Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Annovis Publishes Historical Review of Buntanetap in The Scientist

Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Press Release: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

CStone Pharmaceuticals-B Unveils Latest Clinical Progress and Phase I/II Key Data for Trispecific Antibody CS2009

Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

HENLIUS Receives NMPA Approval for Phase 1 Trial of PD-1 Inhibitor HLX18 in Solid Tumors

Intensified Competition in PD-1/PD-L1 Arena: Can Huahai's HB0025 Bispecific Antibody Stand Out?

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease

Medicenna to Showcase First-in-Class Tumor-Targeted PD-1 x IL-2 Superkine at AACR 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/PD/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":13.83,"timestamp":1787947200000,"preClose":12.63,"halted":0,"volume":3676326,"hourTrading":{"tag":"盘前","latestPrice":13.7,"preClose":13.83,"latestTime":"04:01 EDT","volume":245,"amount":3363.399935,"timestamp":1788163281844,"change":-0.13,"changeRate":-0.0094,"amplitude":0.018077},"delay":0,"changeRate":0.09501187648456051,"floatShares":70635553,"shares":78649873,"eps":2.03,"marketStatus":"Pre-Mkt","change":1.2,"latestTime":"08-31 05:17:22 EDT","open":13.09,"high":14.1899,"low":13.0126,"amount":50610763.178094,"amplitude":0.093215,"askPrice":15.14,"askSize":100,"bidPrice":12.6,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.03,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788183000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":13.83,"preHourTrading":{"tag":"盘前","latestPrice":13.7,"preClose":13.83,"latestTime":"04:01 EDT","volume":245,"amount":3363.399935,"timestamp":1788163281844,"change":-0.13,"changeRate":-0.0094,"amplitude":0.018077},"postHourTrading":{"tag":"盘后","latestPrice":13.8083,"preClose":13.83,"latestTime":"19:39 EDT","volume":78996,"amount":1092384.0875,"timestamp":1787960364573,"change":-0.0217,"changeRate":-0.001569,"amplitude":0.0188},"volumeRatio":2.4194546392100547,"impliedVol":0.6585,"impliedVolPercentile":0.352},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","floatShares":70635553,"roa":"2.29%","roe":"82.56%","lyrEps":1.87,"volumeRatio":2.4194546392100547,"shares":78649873,"dividePrice":0,"high":14.1899,"amplitude":0.093215,"preClose":12.63,"low":13.0126,"week52Low":5.7,"pbRate":"4.69","psRate":"2.20","week52High":17.29,"institutionHeld":0,"latestPrice":13.83,"eps":2.03,"divideRate":0,"volume":3676326,"delay":0,"ttmEps":2.03,"open":13.09,"prevYearClose":13.11,"prevWeekClose":13.83,"prevMonthClose":10.58,"prevQuarterClose":9.65,"fiveDayClose":12.32,"twentyDayClose":10.58,"sixtyDayClose":9.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PD\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"PD","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2026/07","expectedEps":0.12,"defaultRemindTime":1787860800000,"name":null,"time":"Post-Mkt","dateTimestamp":1787803200000,"actualEps":null},{"market":"US","date":"2026-05-28","symbol":"PD","fiscalQuarterEnding":"2026/04","expectedEps":0.03,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1779940800000,"reportTimeType":"post","actualEps":0.1},{"market":"US","date":"2026-03-12","symbol":"PD","fiscalQuarterEnding":"2026/01","expectedEps":0.04,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"post","actualEps":0.13},{"market":"US","date":"2025-11-25","symbol":"PD","fiscalQuarterEnding":"2025/10","expectedEps":0.02,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1764046800000,"reportTimeType":"post","actualEps":0.15},{"date":"2025-09-03","symbol":"PD","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/07","expectedEps":-0.02,"defaultRemindTime":1756929600000,"name":null,"time":"Post-Mkt","dateTimestamp":1756872000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.4444,"sell":0.2222,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.4444,"analysts":9,"updateTime":1784692800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PD","date":"2026-08-28","current":6.530772,"percent":0.960996,"low":-115.332138,"twenty":-29.522867,"median":-21.601223,"eighty":-16.727101,"high":9.29824,"avg":-24.120808,"sd":22.408344,"marketCap":983255111},"quantilePoints":[{"date":"2021-09-03","current":-42.390054,"twenty":-64.090797,"median":-45.440934,"eighty":-39.784241,"marketCap":4025995391},{"date":"2021-09-10","current":-39.410762,"twenty":-63.838675,"median":-45.357157,"eighty":-39.773852,"marketCap":3743037083},{"date":"2021-09-17","current":-42.488469,"twenty":-63.43184,"median":-45.291593,"eighty":-39.773852,"marketCap":4035342362},{"date":"2021-09-24","current":-41.531159,"twenty":-63.322968,"median":-45.131991,"eighty":-39.806871,"marketCap":3944421825},{"date":"2021-10-01","current":-37.845067,"twenty":-63.294318,"median":-44.969953,"eighty":-39.673042,"marketCap":3594335269},{"date":"2021-10-08","current":-35.304169,"twenty":-63.234694,"median":-44.895964,"eighty":-39.361418,"marketCap":3353013468},{"date":"2021-10-15","current":-36.968279,"twenty":-62.977151,"median":-44.757709,"eighty":-39.195032,"marketCap":3511062253},{"date":"2021-10-22","current":-37.567716,"twenty":-62.673,"median":-44.689179,"eighty":-39.048237,"marketCap":3567993805},{"date":"2021-10-29","current":-37.352992,"twenty":-62.144822,"median":-44.662724,"eighty":-38.884343,"marketCap":3547600413},{"date":"2021-11-05","current":-38.927633,"twenty":-61.970673,"median":-44.622066,"eighty":-38.780249,"marketCap":3697151952},{"date":"2021-11-12","current":-37.684024,"twenty":-61.914834,"median":-44.517265,"eighty":-38.690435,"marketCap":3579040225},{"date":"2021-11-19","current":-34.892615,"twenty":-61.891288,"median":-44.350719,"eighty":-38.663132,"marketCap":3313926135},{"date":"2021-11-26","current":-33.094304,"twenty":-61.87812,"median":-44.340807,"eighty":-38.647574,"marketCap":3143131480},{"date":"2021-12-03","current":-27.717262,"twenty":-61.851785,"median":-44.310434,"eighty":-38.490518,"marketCap":2632446965},{"date":"2021-12-10","current":-29.437491,"twenty":-61.634212,"median":-44.193031,"eighty":-38.342002,"marketCap":2964590848},{"date":"2021-12-17","current":-29.446029,"twenty":-61.446371,"median":-44.130431,"eighty":-38.122419,"marketCap":2965450648},{"date":"2021-12-23","current":-30.863263,"twenty":-61.141525,"median":-44.120926,"eighty":-37.910083,"marketCap":3108177469},{"date":"2021-12-31","current":-29.668005,"twenty":-60.679678,"median":-44.096614,"eighty":-37.767931,"marketCap":2987805451},{"date":"2022-01-07","current":-27.243339,"twenty":-60.561077,"median":-44.020576,"eighty":-37.685906,"marketCap":2743622214},{"date":"2022-01-14","current":-26.466422,"twenty":-60.402519,"median":-43.931787,"eighty":-37.609143,"marketCap":2665380403},{"date":"2022-01-21","current":-25.715117,"twenty":-60.229637,"median":-43.82863,"eighty":-37.535067,"marketCap":2589717991},{"date":"2022-01-28","current":-27.448241,"twenty":-60.179262,"median":-43.748751,"eighty":-37.457573,"marketCap":2764257417},{"date":"2022-02-04","current":-27.106738,"twenty":-60.125395,"median":-43.643849,"eighty":-37.310047,"marketCap":2729865412},{"date":"2022-02-11","current":-28.728874,"twenty":-59.884929,"median":-43.550718,"eighty":-37.143446,"marketCap":2893227437},{"date":"2022-02-18","current":-27.106738,"twenty":-59.724487,"median":-43.492185,"eighty":-36.968378,"marketCap":2729865412},{"date":"2022-02-25","current":-28.071482,"twenty":-59.678646,"median":-43.437917,"eighty":-36.905651,"marketCap":2827022827},{"date":"2022-03-04","current":-25.322389,"twenty":-59.583656,"median":-43.360924,"eighty":-36.834452,"marketCap":2550167185},{"date":"2022-03-11","current":-22.70136,"twenty":-59.306192,"median":-43.319423,"eighty":-36.766338,"marketCap":2286208545},{"date":"2022-03-18","current":-28.291592,"twenty":-59.172166,"median":-43.295217,"eighty":-36.444632,"marketCap":3040073042},{"date":"2022-03-25","current":-28.785804,"twenty":-59.048339,"median":-43.241759,"eighty":-36.064649,"marketCap":3093178556},{"date":"2022-04-01","current":-27.724464,"twenty":-59.048339,"median":-43.1764,"eighty":-35.678665,"marketCap":2979132288},{"date":"2022-04-08","current":-25.415442,"twenty":-58.958192,"median":-43.086807,"eighty":-35.293402,"marketCap":2731016361},{"date":"2022-04-14","current":-26.428171,"twenty":-58.866018,"median":-43.039133,"eighty":-34.945236,"marketCap":2839839136},{"date":"2022-04-22","current":-23.843687,"twenty":-58.778063,"median":-42.940117,"eighty":-34.48789,"marketCap":2562123414},{"date":"2022-04-29","current":-23.14693,"twenty":-58.704534,"median":-42.888728,"eighty":-33.407653,"marketCap":2487253345},{"date":"2022-05-06","current":-21.039181,"twenty":-58.614907,"median":-42.82356,"eighty":-33.196501,"marketCap":2260765197},{"date":"2022-05-13","current":-21.537198,"twenty":-58.533862,"median":-42.744231,"eighty":-33.138326,"marketCap":2314279623},{"date":"2022-05-20","current":-19.528801,"twenty":-58.506847,"median":-42.67719,"eighty":-32.784627,"marketCap":2098467346},{"date":"2022-05-27","current":-21.055509,"twenty":-58.47232,"median":-42.506172,"eighty":-32.56425,"marketCap":2262519768},{"date":"2022-06-03","current":-19.41561,"twenty":-58.365647,"median":-42.492303,"eighty":-32.253988,"marketCap":2285547362},{"date":"2022-06-10","current":-18.661968,"twenty":-58.119439,"median":-42.449993,"eighty":-31.627913,"marketCap":2196830881},{"date":"2022-06-17","current":-17.871017,"twenty":-57.794408,"median":-42.412967,"eighty":-30.853018,"marketCap":2103722495},{"date":"2022-06-24","current":-21.251213,"twenty":-57.545961,"median":-42.37641,"eighty":-30.527663,"marketCap":2501629088},{"date":"2022-07-01","current":-18.975364,"twenty":-57.27835,"median":-42.328632,"eighty":-30.205871,"marketCap":2233722883},{"date":"2022-07-08","current":-20.758734,"twenty":-57.119373,"median":-42.300639,"eighty":-29.937792,"marketCap":2443655942},{"date":"2022-07-15","current":-19.512613,"twenty":-57.022546,"median":-42.274674,"eighty":-29.686169,"marketCap":2296966315},{"date":"2022-07-22","current":-19.751391,"twenty":-56.538634,"median":-42.258991,"eighty":-29.576542,"marketCap":2325074507},{"date":"2022-07-29","current":-19.348454,"twenty":-55.37095,"median":-42.1379,"eighty":-29.489533,"marketCap":2277641933},{"date":"2022-08-05","current":-21.340755,"twenty":-54.581356,"median":-41.999461,"eighty":-29.249821,"marketCap":2512169660},{"date":"2022-08-12","current":-21.370602,"twenty":-54.282209,"median":-41.907002,"eighty":-28.899625,"marketCap":2515683184},{"date":"2022-08-19","current":-19.214141,"twenty":-54.164004,"median":-41.742363,"eighty":-28.761236,"marketCap":2261831075},{"date":"2022-08-26","current":-19.318607,"twenty":-54.013801,"median":-41.687142,"eighty":-28.490216,"marketCap":2274128409},{"date":"2022-09-02","current":-16.562766,"twenty":-53.825684,"median":-41.612639,"eighty":-28.401837,"marketCap":2096100841},{"date":"2022-09-09","current":-17.753369,"twenty":-53.67791,"median":-41.5952,"eighty":-28.368118,"marketCap":2246777593},{"date":"2022-09-16","current":-16.597991,"twenty":-53.584381,"median":-41.569297,"eighty":-28.257217,"marketCap":2100558733},{"date":"2022-09-23","current":-15.858267,"twenty":-53.533149,"median":-41.530643,"eighty":-28.105632,"marketCap":2006943000},{"date":"2022-09-30","current":-16.252786,"twenty":-53.345477,"median":-41.466004,"eighty":-27.873415,"marketCap":2056871391},{"date":"2022-10-07","current":-16.182337,"twenty":-53.110426,"median":-41.390601,"eighty":-27.717262,"marketCap":2047955607},{"date":"2022-10-14","current":-14.646529,"twenty":-52.79331,"median":-41.34773,"eighty":-27.636067,"marketCap":1853591514},{"date":"2022-10-21","current":-16.485271,"twenty":-52.578578,"median":-41.307589,"eighty":-27.328715,"marketCap":2086293479},{"date":"2022-10-28","current":-17.922449,"twenty":-52.484531,"median":-41.281723,"eighty":-27.012825,"marketCap":2268175475},{"date":"2022-11-04","current":-14.604259,"twenty":-52.445692,"median":-41.223096,"eighty":-26.683037,"marketCap":1848242043},{"date":"2022-11-11","current":-17.35885,"twenty":-52.440537,"median":-41.165581,"eighty":-26.46868,"marketCap":2196849202},{"date":"2022-11-18","current":-15.442613,"twenty":-51.97825,"median":-41.046215,"eighty":-26.415612,"marketCap":1954339874},{"date":"2022-11-25","current":-15.379208,"twenty":-51.971496,"median":-40.952393,"eighty":-26.24103,"marketCap":1946315669},{"date":"2022-12-02","current":-16.042428,"twenty":-51.941247,"median":-40.886211,"eighty":-26.002015,"marketCap":2129728606},{"date":"2022-12-09","current":-16.110204,"twenty":-51.872986,"median":-40.837833,"eighty":-25.713912,"marketCap":2138726192},{"date":"2022-12-16","current":-18.028246,"twenty":-51.7604,"median":-40.772608,"eighty":-25.598799,"marketCap":2393357876},{"date":"2022-12-23","current":-17.994359,"twenty":-51.70784,"median":-40.745253,"eighty":-25.338499,"marketCap":2388859083},{"date":"2022-12-30","current":-18.001136,"twenty":-51.570726,"median":-40.701201,"eighty":-25.184081,"marketCap":2389758841},{"date":"2023-01-06","current":-16.049206,"twenty":-51.363479,"median":-40.623172,"eighty":-24.85486,"marketCap":2130628364},{"date":"2023-01-13","current":-18.78733,"twenty":-51.102161,"median":-40.574619,"eighty":-24.231092,"marketCap":2494130839},{"date":"2023-01-20","current":-18.882216,"twenty":-50.978262,"median":-40.523325,"eighty":-23.99114,"marketCap":2506727459},{"date":"2023-01-27","current":-19.925957,"twenty":-50.965686,"median":-40.469321,"eighty":-23.312385,"marketCap":2645290284},{"date":"2023-02-03","current":-21.220466,"twenty":-50.951221,"median":-40.311267,"eighty":-22.57339,"marketCap":2817144176},{"date":"2023-02-10","current":-19.627745,"twenty":-50.890949,"median":-40.250171,"eighty":-21.596594,"marketCap":2605700905},{"date":"2023-02-17","current":-20.664708,"twenty":-50.876484,"median":-40.190227,"eighty":-21.430411,"marketCap":2743363971},{"date":"2023-02-24","current":-19.485417,"twenty":-50.857197,"median":-40.120759,"eighty":-21.251213,"marketCap":2586805975},{"date":"2023-03-03","current":-20.834146,"twenty":-50.688437,"median":-40.045986,"eighty":-21.055509,"marketCap":2765857936},{"date":"2023-03-10","current":-18.204462,"twenty":-50.646894,"median":-39.953806,"eighty":-20.967665,"marketCap":2416751599},{"date":"2023-03-17","current":-22.814647,"twenty":-50.628165,"median":-39.81605,"eighty":-20.881589,"marketCap":2929925462},{"date":"2023-03-24","current":-22.508745,"twenty":-50.547877,"median":-39.758269,"eighty":-20.937818,"marketCap":2890640524},{"date":"2023-03-31","current":-24.884826,"twenty":-50.538628,"median":-39.648544,"eighty":-20.967665,"marketCap":3195783993},{"date":"2023-04-06","current":-22.608341,"twenty":-50.398102,"median":-39.410762,"eighty":-20.985573,"marketCap":2903430969},{"date":"2023-04-14","current":-23.753697,"twenty":-50.260054,"median":-39.321908,"eighty":-21.029355,"marketCap":3050521084},{"date":"2023-04-21","current":-24.273021,"twenty":-50.211876,"median":-39.198908,"eighty":-21.041663,"marketCap":3117214118},{"date":"2023-04-28","current":-22.053448,"twenty":-50.10983,"median":-39.086878,"eighty":-21.052864,"marketCap":2832169920},{"date":"2023-05-05","current":-20.085339,"twenty":-50.030853,"median":-39.045525,"eighty":-21.029355,"marketCap":2579419472},{"date":"2023-05-12","current":-21.254175,"twenty":-50.011348,"median":-38.97946,"eighty":-20.981096,"marketCap":2729524925},{"date":"2023-05-19","current":-21.074906,"twenty":-49.936988,"median":-38.858126,"eighty":-20.935287,"marketCap":2706502616},{"date":"2023-05-26","current":-18.98821,"twenty":-49.739821,"median":-38.781427,"eighty":-20.865452,"marketCap":2438522942},{"date":"2023-06-02","current":-23.7011,"twenty":-49.634889,"median":-38.748697,"eighty":-20.83367,"marketCap":2555476271},{"date":"2023-06-09","current":-19.16437,"twenty":-49.587066,"median":-38.685442,"eighty":-20.780404,"marketCap":2066321490},{"date":"2023-06-16","current":-19.591955,"twenty":-49.518553,"median":-38.668128,"eighty":-20.758997,"marketCap":2112424156},{"date":"2023-06-23","current":-18.642716,"twenty":-49.490829,"median":-38.652026,"eighty":-20.740419,"marketCap":2010076237},{"date":"2023-06-30","current":-18.830853,"twenty":-49.425691,"median":-38.650282,"eighty":-20.728887,"marketCap":2030361410},{"date":"2023-07-07","current":-18.753888,"twenty":-49.321753,"median":-38.534252,"eighty":-20.640309,"marketCap":2022062930},{"date":"2023-07-14","current":-21.12271,"twenty":-49.135663,"median":-38.486364,"eighty":-20.586625,"marketCap":2277471700},{"date":"2023-07-21","current":-20.626711,"twenty":-49.077653,"median":-38.375503,"eighty":-20.595005,"marketCap":2223992607},{"date":"2023-07-28","current":-21.105606,"twenty":-49.061015,"median":-38.330676,"eighty":-20.595005,"marketCap":2275627593},{"date":"2023-08-04","current":-20.883262,"twenty":-49.007339,"median":-38.158206,"eighty":-20.613914,"marketCap":2251654207},{"date":"2023-08-11","current":-20.549746,"twenty":-48.954208,"median":-37.988814,"eighty":-20.586625,"marketCap":2215694127},{"date":"2023-08-18","current":-20.01954,"twenty":-48.941266,"median":-37.845067,"eighty":-20.541194,"marketCap":2158526822},{"date":"2023-08-25","current":-20.66947,"twenty":-48.894876,"median":-37.770349,"eighty":-20.506987,"marketCap":2228602874},{"date":"2023-09-01","current":-25.511357,"twenty":-48.832826,"median":-37.755599,"eighty":-20.541194,"marketCap":2375209352},{"date":"2023-09-07","current":-24.043412,"twenty":-48.807682,"median":-37.686377,"eighty":-20.560008,"marketCap":2238537799},{"date":"2023-09-14","current":-23.412009,"twenty":-48.750972,"median":-37.671633,"eighty":-20.577111,"marketCap":2179751687},{"date":"2023-09-22","current":-22.590183,"twenty":-48.595885,"median":-37.578261,"eighty":-20.58462,"marketCap":2103236431},{"date":"2023-09-28","current":-22.048981,"twenty":-48.583225,"median":-37.547623,"eighty":-20.587293,"marketCap":2052848336},{"date":"2023-10-05","current":-21.978825,"twenty":-48.576545,"median":-37.531928,"eighty":-20.595005,"marketCap":2046316545},{"date":"2023-10-11","current":-21.497757,"twenty":-48.562801,"median":-37.500901,"eighty":-20.605423,"marketCap":2001527127},{"date":"2023-10-20","current":-20.345196,"twenty":-48.534663,"median":-37.448341,"eighty":-20.589221,"marketCap":1894219146},{"date":"2023-10-27","current":-19.894194,"twenty":-48.514606,"median":-37.410785,"eighty":-20.580532,"marketCap":1852229066},{"date":"2023-11-03","current":-20.485508,"twenty":-48.433814,"median":-37.299311,"eighty":-20.506205,"marketCap":1907282726},{"date":"2023-11-10","current":-20.746087,"twenty":-48.370598,"median":-37.219715,"eighty":-20.506987,"marketCap":1931543661},{"date":"2023-11-17","current":-21.217133,"twenty":-48.32991,"median":-37.120374,"eighty":-20.524091,"marketCap":1975399966},{"date":"2023-11-24","current":-21.858558,"twenty":-48.320008,"median":-37.057747,"eighty":-20.549746,"marketCap":2035119191},{"date":"2023-11-30","current":-22.048981,"twenty":-48.252059,"median":-36.968279,"eighty":-20.57027,"marketCap":2052848336},{"date":"2023-12-07","current":-26.625426,"twenty":-48.121131,"median":-36.925787,"eighty":-20.578821,"marketCap":2015198621},{"date":"2023-12-15","current":-28.276615,"twenty":-48.00719,"median":-36.911135,"eighty":-20.582242,"marketCap":2140172179},{"date":"2024-01-05","current":-26.103359,"twenty":-47.918569,"median":-36.904212,"eighty":-20.585288,"marketCap":1975684923},{"date":"2024-01-12","current":-31.117632,"twenty":-47.865829,"median":-36.842529,"eighty":-20.591149,"marketCap":2355200212},{"date":"2024-01-19","current":-31.627558,"twenty":-47.844972,"median":-36.829603,"eighty":-20.601178,"marketCap":2393794988},{"date":"2024-01-26","current":-29.053645,"twenty":-47.78321,"median":-36.766338,"eighty":-20.619869,"marketCap":2198983265},{"date":"2024-02-02","current":-29.32075,"twenty":-47.731847,"median":-36.504107,"eighty":-20.628421,"marketCap":2219199576},{"date":"2024-02-09","current":-29.393596,"twenty":-47.672575,"median":-36.388531,"eighty":-20.635263,"marketCap":2224713115},{"date":"2024-02-16","current":-29.733547,"twenty":-47.618326,"median":-36.095963,"eighty":-20.635379,"marketCap":2250442965},{"date":"2024-02-23","current":-28.10664,"twenty":-47.602066,"median":-35.89466,"eighty":-20.635842,"marketCap":2127307254},{"date":"2024-03-01","current":-29.332891,"twenty":-47.570415,"median":-35.678665,"eighty":-20.651153,"marketCap":2220118499},{"date":"2024-03-08","current":-29.55143,"twenty":-47.518149,"median":-35.35785,"eighty":-20.660918,"marketCap":2236659117},{"date":"2024-03-15","current":-26.009561,"twenty":-47.49129,"median":-35.24315,"eighty":-20.664708,"marketCap":2126463652},{"date":"2024-03-22","current":-25.786705,"twenty":-47.380514,"median":-34.925503,"eighty":-20.66947,"marketCap":2108243640},{"date":"2024-03-28","current":-24.935846,"twenty":-47.342533,"median":-34.589879,"eighty":-20.66947,"marketCap":2038679948},{"date":"2024-04-05","current":-25.071983,"twenty":-47.312176,"median":-34.414946,"eighty":-20.689994,"marketCap":2049810139},{"date":"2024-04-12","current":-25.888808,"twenty":-47.269427,"median":-33.423363,"eighty":-20.697474,"marketCap":2116591283},{"date":"2024-04-19","current":-23.631195,"twenty":-47.158961,"median":-33.184171,"eighty":-20.697474,"marketCap":1932015619},{"date":"2024-04-26","current":-22.916473,"twenty":-46.951231,"median":-33.003753,"eighty":-20.698257,"marketCap":1873582118},{"date":"2024-05-03","current":-23.897861,"twenty":-46.656905,"median":-32.649248,"eighty":-20.698257,"marketCap":1953817432},{"date":"2024-05-10","current":-23.114516,"twenty":-46.598159,"median":-32.247909,"eighty":-20.698257,"marketCap":1889773514},{"date":"2024-05-17","current":-24.517522,"twenty":-46.43348,"median":-31.759443,"eighty":-20.698257,"marketCap":2004479038},{"date":"2024-05-24","current":-22.904066,"twenty":-46.181838,"median":-31.451512,"eighty":-20.698257,"marketCap":1872567685},{"date":"2024-05-31","current":-20.986625,"twenty":-46.068748,"median":-31.128449,"eighty":-20.698257,"marketCap":1715803469},{"date":"2024-06-07","current":-20.224161,"twenty":-45.830813,"median":-30.643949,"eighty":-20.66395,"marketCap":1892880316},{"date":"2024-06-14","current":-21.429439,"twenty":-45.725202,"median":-30.31849,"eighty":-20.645029,"marketCap":2005688335},{"date":"2024-06-21","current":-21.357939,"twenty":-45.671397,"median":-29.967092,"eighty":-20.641966,"marketCap":1998996334},{"date":"2024-06-28","current":-23.247571,"twenty":-45.51108,"median":-29.932669,"eighty":-20.635726,"marketCap":2175856364},{"date":"2024-07-05","current":-22.542789,"twenty":-45.42729,"median":-29.794252,"eighty":-20.635726,"marketCap":2109892353},{"date":"2024-07-12","current":-21.439653,"twenty":-45.27192,"median":-29.668005,"eighty":-20.635726,"marketCap":2006644335},{"date":"2024-07-15","current":-21.807365,"twenty":-45.165128,"median":-29.6527,"eighty":-20.635726,"marketCap":2041060341},{"date":"2024-08-02","current":-20.438659,"twenty":-44.67116,"median":-29.473821,"eighty":-20.619869,"marketCap":1912956320},{"date":"2024-08-09","current":-18.937169,"twenty":-44.592228,"median":-29.326821,"eighty":-20.554877,"marketCap":1772424296},{"date":"2024-08-16","current":-19.846234,"twenty":-44.342086,"median":-29.065787,"eighty":-20.488395,"marketCap":1857508310},{"date":"2024-08-23","current":-19.366166,"twenty":-44.293477,"median":-28.968658,"eighty":-20.439367,"marketCap":1812576303},{"date":"2024-08-30","current":-20.193518,"twenty":-44.126836,"median":-28.878841,"eighty":-20.396729,"marketCap":1890012316},{"date":"2024-09-06","current":-20.851386,"twenty":-44.070828,"median":-28.815003,"eighty":-20.350301,"marketCap":1731811836},{"date":"2024-09-13","current":-19.495653,"twenty":-43.902513,"median":-28.750118,"eighty":-20.261779,"marketCap":1619211496},{"date":"2024-09-20","current":-20.358392,"twenty":-43.724824,"median":-28.493474,"eighty":-20.244564,"marketCap":1690866258},{"date":"2024-09-27","current":-20.324779,"twenty":-43.52784,"median":-28.425739,"eighty":-20.226358,"marketCap":1688074514},{"date":"2024-10-04","current":-19.753355,"twenty":-43.367535,"median":-28.373476,"eighty":-20.209123,"marketCap":1640614867},{"date":"2024-10-11","current":-20.30237,"twenty":-43.311657,"median":-28.264591,"eighty":-20.195561,"marketCap":1686213351},{"date":"2024-10-18","current":-21.030656,"twenty":-43.248031,"median":-28.136018,"eighty":-20.195561,"marketCap":1746701137},{"date":"2024-10-25","current":-20.078282,"twenty":-43.248031,"median":-28.049113,"eighty":-20.145499,"marketCap":1667601725},{"date":"2024-10-31","current":-20.649706,"twenty":-43.248031,"median":-27.765641,"eighty":-20.132647,"marketCap":1715061372},{"date":"2024-11-08","current":-22.688907,"twenty":-43.252213,"median":-27.636067,"eighty":-20.132233,"marketCap":1884427173},{"date":"2024-11-15","current":-21.960621,"twenty":-43.252213,"median":-27.448241,"eighty":-20.132233,"marketCap":1823939387},{"date":"2024-11-22","current":-22.229527,"twenty":-43.231304,"median":-27.106738,"eighty":-20.132233,"marketCap":1846273338},{"date":"2024-11-29","current":-25.707412,"twenty":-43.145724,"median":-26.876224,"eighty":-20.132233,"marketCap":1914893729},{"date":"2024-12-06","current":-25.40483,"twenty":-43.145724,"median":-26.625426,"eighty":-20.132233,"marketCap":1892354961},{"date":"2024-12-13","current":-24.521289,"twenty":-43.145724,"median":-26.466422,"eighty":-20.132233,"marketCap":1826541758},{"date":"2024-12-20","current":-22.572657,"twenty":-43.145724,"median":-26.327469,"eighty":-20.132233,"marketCap":1681392092},{"date":"2024-12-27","current":-22.173248,"twenty":-43.145724,"median":-26.203648,"eighty":-20.132233,"marketCap":1651640919},{"date":"2025-01-03","current":-21.785943,"twenty":-43.145724,"median":-26.12294,"eighty":-20.132233,"marketCap":1622791296},{"date":"2025-01-10","current":-21.434947,"twenty":-43.151859,"median":-25.994723,"eighty":-20.130744,"marketCap":1596646325},{"date":"2025-01-17","current":-22.584761,"twenty":-43.151859,"median":-25.832017,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-24","current":-22.584761,"twenty":-43.151859,"median":-25.722549,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-31","current":-22.330591,"twenty":-43.151859,"median":-25.688138,"eighty":-20.130744,"marketCap":1663361078},{"date":"2025-02-07","current":-23.032583,"twenty":-43.151859,"median":-25.544418,"eighty":-20.130744,"marketCap":1715651020},{"date":"2025-02-14","current":-23.601438,"twenty":-43.151859,"median":-25.410136,"eighty":-20.130744,"marketCap":1758023904},{"date":"2025-02-21","current":-22.149042,"twenty":-43.151859,"median":-25.353801,"eighty":-20.130744,"marketCap":1649837817},{"date":"2025-02-28","current":-21.229191,"twenty":-43.151859,"median":-25.248903,"eighty":-20.130744,"marketCap":1581319962},{"date":"2025-03-07","current":-20.902402,"twenty":-43.157994,"median":-25.114351,"eighty":-20.129255,"marketCap":1556978093},{"date":"2025-03-14","current":-25.841364,"twenty":-43.157994,"median":-25.015259,"eighty":-20.118618,"marketCap":1407320673},{"date":"2025-03-21","current":-31.526661,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1716941957},{"date":"2025-03-28","current":-31.810986,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1732426315},{"date":"2025-04-04","current":-28.415807,"twenty":-43.157994,"median":-25.140052,"eighty":-20.118618,"marketCap":1547524873},{"date":"2025-04-11","current":-25.672904,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1398146368},{"date":"2025-04-17","current":-25.238054,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1374464410},{"date":"2025-04-25","current":-26.22483,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1428204238},{"date":"2025-05-02","current":-26.007405,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1416363259},{"date":"2025-05-09","current":-26.208105,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1427293394},{"date":"2025-05-16","current":-28.064582,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1528397138},{"date":"2025-05-23","current":-26.826931,"twenty":-43.110374,"median":-25.054079,"eighty":-20.118618,"marketCap":1460994642},{"date":"2025-05-30","current":-40.212905,"twenty":-43.110374,"median":-25.054079,"eighty":-20.118618,"marketCap":1483896395},{"date":"2025-06-06","current":-38.417271,"twenty":-42.89345,"median":-25.054079,"eighty":-20.118618,"marketCap":1417635735},{"date":"2025-06-13","current":-37.443101,"twenty":-42.85482,"median":-25.054079,"eighty":-20.118618,"marketCap":1381687885},{"date":"2025-06-20","current":-35.644634,"twenty":-42.692819,"median":-25.045717,"eighty":-20.116377,"marketCap":1315322623},{"date":"2025-06-27","current":-37.218293,"twenty":-42.4845,"median":-25.045717,"eighty":-20.116377,"marketCap":1373392227},{"date":"2025-07-03","current":-39.940973,"twenty":-42.385562,"median":-25.045717,"eighty":-20.116377,"marketCap":1473861860},{"date":"2025-07-11","current":-39.516335,"twenty":-42.275719,"median":-25.045717,"eighty":-20.116377,"marketCap":1458192284},{"date":"2025-07-18","current":-36.593825,"twenty":-42.275719,"median":-25.045717,"eighty":-20.116377,"marketCap":1350348733},{"date":"2025-07-25","current":-36.743697,"twenty":-42.001222,"median":-25.045717,"eighty":-20.116377,"marketCap":1355879172},{"date":"2025-08-01","current":-40.265697,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1485844477},{"date":"2025-08-08","current":-38.941825,"twenty":-41.552011,"median":-25.045717,"eighty":-20.116377,"marketCap":1436992270},{"date":"2025-08-15","current":-38.667059,"twenty":-41.27534,"median":-25.045717,"eighty":-20.116377,"marketCap":1426853133},{"date":"2025-08-22","current":-39.441399,"twenty":-41.020287,"median":-25.045717,"eighty":-20.116377,"marketCap":1455427065},{"date":"2025-08-29","current":-42.263994,"twenty":-40.940123,"median":-25.045717,"eighty":-20.116377,"marketCap":1559583657},{"date":"2025-09-05","current":-111.301894,"twenty":-40.946258,"median":-25.037354,"eighty":-20.114136,"marketCap":1545092897},{"date":"2025-09-12","current":-111.369065,"twenty":-41.159237,"median":-25.045717,"eighty":-20.116377,"marketCap":1546025361},{"date":"2025-09-19","current":-110.361504,"twenty":-41.502219,"median":-25.045717,"eighty":-20.116377,"marketCap":1532038401},{"date":"2025-09-26","current":-108.816577,"twenty":-41.627318,"median":-25.045717,"eighty":-20.116377,"marketCap":1510591728},{"date":"2025-10-03","current":-110.630187,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1535768257},{"date":"2025-10-10","current":-109.824138,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1524578689},{"date":"2025-10-17","current":-105.659553,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1466765919},{"date":"2025-10-24","current":-107.540334,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1492874912},{"date":"2025-10-31","current":-105.793895,"twenty":-41.746269,"median":-25.045717,"eighty":-20.116377,"marketCap":1468630847},{"date":"2025-11-07","current":-101.562139,"twenty":-41.812397,"median":-25.045717,"eighty":-20.116377,"marketCap":1409885613},{"date":"2025-11-14","current":-104.719163,"twenty":-41.812397,"median":-25.045717,"eighty":-20.116377,"marketCap":1453711422},{"date":"2025-11-21","current":-98.740968,"twenty":-41.812397,"median":-25.045717,"eighty":-20.116377,"marketCap":1370722124},{"date":"2025-11-28","current":6.997444,"twenty":-41.746269,"median":-24.978468,"eighty":-20.091839,"marketCap":1065227860},{"date":"2025-12-05","current":7.219871,"twenty":-41.569584,"median":-24.845699,"eighty":-20.051536,"marketCap":1099088196},{"date":"2025-12-12","current":7.833049,"twenty":-41.149298,"median":-24.524361,"eighty":-20.010479,"marketCap":1192432905},{"date":"2025-12-19","current":7.79698,"twenty":-40.783904,"median":-24.456235,"eighty":-19.933106,"marketCap":1186942040},{"date":"2025-12-26","current":7.839061,"twenty":-40.638471,"median":-24.290539,"eighty":-19.921421,"marketCap":1193348049},{"date":"2026-01-02","current":7.881142,"twenty":-40.445544,"median":-24.213538,"eighty":-19.883804,"marketCap":1199754059},{"date":"2026-01-09","current":7.616633,"twenty":-40.245714,"median":-24.133436,"eighty":-19.850083,"marketCap":1159487714},{"date":"2026-01-16","current":7.105652,"twenty":-40.140803,"median":-24.036721,"eighty":-19.806911,"marketCap":1081700456},{"date":"2026-01-23","current":6.738947,"twenty":-40.000922,"median":-23.900481,"eighty":-19.757821,"marketCap":1025876659},{"date":"2026-01-30","current":6.318139,"twenty":-39.844633,"median":-23.836174,"eighty":-19.718173,"marketCap":961816564},{"date":"2026-02-06","current":4.749124,"twenty":-39.429144,"median":-23.74822,"eighty":-19.674843,"marketCap":722963925},{"date":"2026-02-13","current":4.075831,"twenty":-39.135469,"median":-23.649661,"eighty":-19.608912,"marketCap":620467774},{"date":"2026-02-20","current":4.021727,"twenty":-38.923318,"median":-23.601935,"eighty":-19.561129,"marketCap":612231476},{"date":"2026-02-27","current":4.256177,"twenty":-38.673097,"median":-23.492961,"eighty":-19.508534,"marketCap":647922100},{"date":"2026-03-06","current":4.664962,"twenty":-38.60711,"median":-23.396809,"eighty":-19.489511,"marketCap":710151906},{"date":"2026-03-13","current":3.826831,"twenty":-38.317356,"median":-23.305813,"eighty":-19.445457,"marketCap":665309840},{"date":"2026-03-20","current":3.358288,"twenty":-37.997629,"median":-23.223191,"eighty":-19.406656,"marketCap":583851876},{"date":"2026-03-27","current":3.07113,"twenty":-37.726969,"median":-23.142007,"eighty":-19.330546,"marketCap":533928310},{"date":"2026-04-02","current":3.075998,"twenty":-37.531928,"median":-23.103807,"eighty":-19.288759,"marketCap":534774472},{"date":"2026-04-10","current":2.95432,"twenty":-37.33152,"median":-23.026783,"eighty":-19.228348,"marketCap":513620418},{"date":"2026-04-17","current":3.119801,"twenty":-37.141321,"median":-22.922472,"eighty":-19.200424,"marketCap":542389931},{"date":"2026-04-24","current":2.998124,"twenty":-36.968415,"median":-22.886122,"eighty":-19.150518,"marketCap":521235878},{"date":"2026-05-01","current":3.236611,"twenty":-36.792556,"median":-22.796862,"eighty":-19.059356,"marketCap":562697823},{"date":"2026-05-08","current":3.60651,"twenty":-36.546214,"median":-22.703577,"eighty":-18.989041,"marketCap":627006145},{"date":"2026-05-15","current":2.967148,"twenty":-36.114067,"median":-22.620757,"eighty":-18.890004,"marketCap":515850488},{"date":"2026-05-22","current":3.10823,"twenty":-35.890938,"median":-22.561376,"eighty":-18.847957,"marketCap":540378298},{"date":"2026-05-29","current":3.010498,"twenty":-35.390059,"median":-22.540072,"eighty":-18.78733,"marketCap":573791883},{"date":"2026-06-05","current":3.84405,"twenty":-34.84372,"median":-22.428622,"eighty":-18.581645,"marketCap":732664367},{"date":"2026-06-12","current":3.548665,"twenty":-32.834795,"median":-22.336643,"eighty":-18.476527,"marketCap":676364895},{"date":"2026-06-18","current":3.487969,"twenty":-32.200072,"median":-22.276208,"eighty":-18.281834,"marketCap":664796510},{"date":"2026-06-26","current":3.463691,"twenty":-31.676123,"median":-22.229527,"eighty":-18.139398,"marketCap":660169156},{"date":"2026-07-02","current":4.058507,"twenty":-31.506957,"median":-22.173248,"eighty":-18.004593,"marketCap":773539326},{"date":"2026-07-10","current":4.232501,"twenty":-31.379147,"median":-22.100628,"eighty":-17.925594,"marketCap":806702029},{"date":"2026-07-17","current":4.309382,"twenty":-30.85814,"median":-22.017878,"eighty":-17.790437,"marketCap":821355317},{"date":"2026-07-24","current":3.492016,"twenty":-30.583371,"median":-21.935122,"eighty":-17.680267,"marketCap":665567735},{"date":"2026-07-31","current":4.196084,"twenty":-30.20705,"median":-21.898647,"eighty":-17.533486,"marketCap":799760999},{"date":"2026-08-07","current":4.491469,"twenty":-29.939946,"median":-21.843368,"eighty":-17.408164,"marketCap":856060471},{"date":"2026-08-14","current":4.892059,"twenty":-29.794252,"median":-21.785943,"eighty":-17.253175,"marketCap":932411810},{"date":"2026-08-21","current":4.904198,"twenty":-29.6527,"median":-21.707843,"eighty":-16.923368,"marketCap":934725487},{"date":"2026-08-28","current":5.299253,"twenty":-29.522867,"median":-21.601223,"eighty":-16.727101,"marketCap":983255111}],"updateTime":1788146283845},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PD\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628781274","title":"Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2628781274","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628781274?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:05","pubTimestamp":1776456300,"startTime":"0","endTime":"0","summary":"Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-immune environment in a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/17/3276488/0/en/Pyxis-Oncology-to-Present-New-Preclinical-Data-Showing-Synergistic-Anti-Tumor-Activity-in-a-HNSCC-model-with-maMICVO-in-Combination-with-Anti-PD-1-at-AACR-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK4585","BK4107","BK4139","ADC","BK4023","BK4080","BK4588","LU0210528500.USD","LU1169590202.USD","L","PYXS","LU1169589451.USD","BK4231","LU0053666078.USD","LU2487616109.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627746478","title":"SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627746478","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627746478?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:00","pubTimestamp":1776211200,"startTime":"0","endTime":"0","summary":"SHANGHAI, April 15, 2026 /PRNewswire/ -- Mabwell , an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that 18F-FD4 , an α-synuclein  targeted PET tracer independently developed by its incubated company SynuSight Biotech, has recently been approved by the National Medical Products Administration  to initiate a Phase I clinical trial.Abnormal aggregation and deposition of α-syn protein are key pathological features of α-synucleinopathies such as PD and MSA. However, current clinical diagnosis still relies mainly on clinical symptom assessment and indirect functional imaging biomarkers. As an α-syn-specific PET molecular tracer validated through IIT  studies, SST001 enables in vivo, realtime, qualitative, and quantitative detection. It is expected to provide more objective and quantifiable imaging evidence for early diagnosis and disease subtyping of PD and MSA, as well as potential imaging support for subject screening and efficacy evaluation","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/sst001-an--syn-pet-tracer-from-mabwells-incubated-company-synusight-biotech-received-nmpa-approval-to-initiate-a-clinical-trial-302741812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XBI","MSA","LU0154245756.USD","LU0757428866.USD","PD","LU0053671581.USD","LU2211815571.USD","688062","LU1815336091.USD","LU2125909759.SGD","BK4023","LU0154245673.USD","BK4143","LU0728928796.USD","BK0239","LU1169590202.USD","LU2125909916.SGD","LU1923622291.USD","BK4581","LU1169589451.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626874261","title":"Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2626874261","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626874261?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:30","pubTimestamp":1775737800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., April  09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270958/0/en/Annovis-Announces-10-Million-Underwritten-Offering-of-Common-Stock-and-Accompanying-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1169589451.USD","BK4023","AD","ANVS","BK4139","LU1169590202.USD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215188","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215188","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626215188?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:34","pubTimestamp":1775723640,"startTime":"0","endTime":"0","summary":"NANJING, China, April  09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270693/0/en/Leads-Biolabs-Opamtistomig-PD-L1-4-1BB-Bispecific-Antibody-Advances-to-Expansion-Phase-in-First-Line-Biliary-Tract-Cancer-Following-Positive-Safety-and-Preliminary-Efficacy-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","IE00B2PGVK34.USD","ORR","BK4183","OC","PD","LU1169590202.USD","LU0868494617.USD","BTC","BK4023","LU2041044095.USD","IE0009354923.USD","LU2023250843.SGD","BK4086","HCC","BK4006","LU2023250504.SGD","LU2106854487.HKD","IE00B3CCJ633.GBP","IE00BGHQF417.EUR","LU2360108059.USD","ODD","LU1917777945.USD","LU2092937221.SGD","LU2048586759.USD","LU2298321311.HKD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625093917","title":"Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2625093917","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625093917?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:00","pubTimestamp":1775642400,"startTime":"0","endTime":"0","summary":"Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobruti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3269913/0/en/Nurix-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","NRIX","BK4139","PK","LU1169589451.USD","LU1169590202.USD","BK4181","BK4218","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625966439","title":"Positioning Ivonescimab to Anchor a ~$200B PD-1xVEGF Market: Early NSCLC Validation and Commercial Head Start Support Buy Rating on Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2625966439","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625966439?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:25","pubTimestamp":1775593523,"startTime":"0","endTime":"0","summary":"Stephen Willey, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Summit Therapeutics (SMMT). Stephen Willey has given his Buy rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positioning-ivonescimab-to-anchor-a-200b-pd-1xvegf-market-early-nsclc-validation-and-commercial-head-start-support-buy-rating-on-summit-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positioning-ivonescimab-to-anchor-a-200b-pd-1xvegf-market-early-nsclc-validation-and-commercial-head-start-support-buy-rating-on-summit-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PD","SMMF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625248958","title":"Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2625248958","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625248958?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:00","pubTimestamp":1775563200,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, N.J., April  07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations totaling $2 million to multiple patient assista","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/07/3269073/0/en/Amneal-Announces-2-Million-Donation-to-Support-Patient-Access-to-Essential-Medicines-During-Parkinson-s-Awareness-Month.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","MDCO","PD","LU1169589451.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624305518","title":"Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset","url":"https://stock-news.laohu8.com/highlight/detail?id=2624305518","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624305518?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:30","pubTimestamp":1775043000,"startTime":"0","endTime":"0","summary":"Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancerPHILADELPHIA, April  01, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASD","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/01/3266511/0/en/Medicus-Pharma-Ltd-Clarifies-Positive-SkinJect-Phase-2-Dataset.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4139","MNA","BK4215","PD","BK4567","BK4104","CSR","BK4023","LU1169590202.USD","MDCX","BCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623584887","title":"Annovis Publishes Historical Review of Buntanetap in The Scientist","url":"https://stock-news.laohu8.com/highlight/detail?id=2623584887","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623584887?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March  31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3265424/0/en/Annovis-Publishes-Historical-Review-of-Buntanetap-in-The-Scientist.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4132","LU1169589451.USD","PD","BK4139","LU1169590202.USD","AD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622247863","title":"Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2622247863","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622247863?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:32","pubTimestamp":1774531920,"startTime":"0","endTime":"0","summary":"-- The global, multicenter Phase I/II clinical trial of CS2009. Australia and China, and the Phase II IND application has been approved. in the US. CS2009 demonstrates an excellent safety profile with a >=Grade. 3 TRAE rate of 23%, along with broad-spectrum anti-tumor activity.Notably, monotherapy data in lung cancer are encouraging: in first-line. NSCLC patients with PD-L1 TPS >=50%, the ORR reached 90% with a DCR of. 100%, while the ORR was 25% in IO-pretreated NSCLC .Furthermore, significant benefits were observed in patients with heavily. pre-treated \"cold tumors,\" achieving an ORR of 40% in non-clear cell. renal cell carcinoma  and 33.3% in soft tissue sarcoma .-- The global Phase Ib multicenter trial of CS5001  is being. advanced rapidly and efficiently in Australia and China, with its R&D. progress ranking among the top two globally. In combination with R-CHOP. rate exceeds 90%, and the ORR reaches 100%. Additionally, the combination. complementing its successful NRDL renewal at","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5TLWC47.USD","BK4588","LU0347712357.USD","PD","BK4533","BK4567","BK1574","MTD","ORR","BK4213","BK4023","BK4156","L","PK","BK4121","BK4218","CRC","LU1169589451.USD","LU0053666078.USD","HCC","LU1721428933.USD","BK4006","LU2211817866.USD","LU2413666699.HKD","LU1093756168.USD","PROC","BK4098","R","LU2487616109.SGD","IE00BFXG0V08.USD","CC","BK4007","LU0210528500.USD","LU0456854461.SGD","LU1093756325.SGD","LU1169590202.USD","BK4232","IE00BYQQ9H92.USD","LU0266512127.USD","BK4107","LU2413666426.HKD","BK4022","02616","BK4585","BK1161","BK4181","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852318","title":"Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852318","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852318?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"200g Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin CancerPHILADELPHIA, March  26, 2026 (GLOBE NEWSWI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262893/0/en/Medicus-Pharma-Business-Update-Call-to-Highlight-80-Overall-Response-Rate-ORR-in-Phase-2-SkinJect-Study-and-Agentic-AI-enabled-Drug-Development-Plan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","CSR","BK4161","BK4567","MDCX","PD","AGIX","BK4215","CR","BK4139","CHAT","MNA","AIPO","BK4104","PR","BK4213","LU1169589451.USD","BCC","LU1169590202.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622518778","title":"Press Release: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622518778","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622518778?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., March 26, 2026  -- Gain Therapeutics, Inc.  , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update.Mr. Mack continued, \"We will continue to follow patients in the Phase 1b nine-month extension study that is expected to complete in September 2026 and look forward to presenting longer-term follow up at additional scientific conferences throughout the balance of the year. To date, MDS-UPDRS scores remained stable and durable across the overall study population after 150 days of treatment with GT-02287 and are becoming more encouraging with the passage of time. We believe the totality of the data continues to support the potential of GT-02287 in both idiopathic and GBA1 Parkinson's disease and we hope to one day shift the treatment paradigm away from symptomatic relief ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4212","DDC","GT","03160","BK4604","BK4232","BK4555","TM","BK4022","LU1169589451.USD","CSF","BK4099","IND","LU1169590202.USD","R","BK4585","BK4588","GANX","BK4139","BK4023","PD","BK4119"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189079157","title":"CStone Pharmaceuticals-B Unveils Latest Clinical Progress and Phase I/II Key Data for Trispecific Antibody CS2009","url":"https://stock-news.laohu8.com/highlight/detail?id=1189079157","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189079157?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:21","pubTimestamp":1774516865,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) has announced the latest clinical progress for its internally developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009. The data demonstrate an excellent safety...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU1169589451.USD","PD","BK1161","02616","BK4023","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621068695","title":"Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068695","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621068695?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:24","pubTimestamp":1774344240,"startTime":"0","endTime":"0","summary":"CHENGDU, China, March 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  today announced that the Investigational New Drug  application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined Tumor-Associated Antigen-targeting and Immuno-Oncology mechanisms , has been approved by the Center for Drug Evaluation  of the National Medical Products Administration  of China for the treatment of advanced solid tumors. The approval marks SKB103 as the Company's first TAA-PD-L1 bsADC candidate and its second bsADC program for tumor therapy to enter the clinical stage, following SKB571.Kelun-Biotech  is a holding subsidiary of Kelun Pharmaceutical , which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-receives-ind-approval-for-skb103-a-novel-taa-pd-l1-bispecific-adc-302723152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1979443071.USD","LU1169589451.USD","PD","LU1064130708.USD","BK0239","XBI","IND.AU","002422","ADC","IND","LU1223082519.USD","BK7050","BK0060","BK4080","BK4023","LU1169590202.USD","BK7095","LU1223082196.USD","LU1064131003.USD","LU1223083913.SGD","BK4231","CDE.AU","LU2148510915.USD","BK4585","BK4588","CDE","LU1934453819.USD","BK4581","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621670562","title":"Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2621670562","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621670562?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:30","pubTimestamp":1774269000,"startTime":"0","endTime":"0","summary":"OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capva","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260381/0/en/Vaxcyte-Completes-Enrollment-of-OPUS-1-and-OPUS-2-Phase-3-Trials-Evaluating-VAX-31-for-the-Prevention-of-Invasive-Pneumococcal-Disease-and-Pneumonia-in-Adults.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX","BK4213","BK4139","LU1261432733.SGD","BK4585","LU0053671581.USD","CI","LU1169590202.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU1059921491.USD","IE0009354923.USD","IE0002270589.USD","PD","IE00BSNM7G36.USD","BK4023","BK4233","LU1169589451.USD","LU0868494617.USD","BK4588","OPUS","LU0289739699.SGD","LU0058720904.USD","LB","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621261758","title":"Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621261758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621261758?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:05","pubTimestamp":1774022700,"startTime":"0","endTime":"0","summary":"Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March  20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eis","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/20/3259865/0/en/Results-from-Real-World-Long-Term-Treatment-Persistence-with-LEQEMBI-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI","CDR","CSF","UBCP","BK4023","AD","LU1169589451.USD","BK4211","BK4132","PD","LU1169590202.USD","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164631567","title":"HENLIUS Receives NMPA Approval for Phase 1 Trial of PD-1 Inhibitor HLX18 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1164631567","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164631567?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:18","pubTimestamp":1774001918,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) has announced that the investigational new drug application for a Phase 1 clinical trial of its self-developed HLX18, a biosimilar of nivolumab, has been approved by the National...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","02696","HK0000306701.USD","HK0000320264.USD","BK1161","HK0000306685.HKD","LU1169589451.USD","LU1169590202.USD","HK0000165453.HKD","PD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129871203","title":"Intensified Competition in PD-1/PD-L1 Arena: Can Huahai's HB0025 Bispecific Antibody Stand Out?","url":"https://stock-news.laohu8.com/highlight/detail?id=1129871203","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129871203?lang=en_us&edition=fundamental","pubTime":"2026-03-20 16:31","pubTimestamp":1773995482,"startTime":"0","endTime":"0","summary":"The recommendation levels in the CSCO (Chinese Society of Clinical Oncology) guidelines serve as a bridge connecting high-level medical evidence with complex clinical decisions. They are not merely...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","600521","BK4023","LU1169589451.USD","PD","BK0239","BK0185","BK0201","BK0070","BK0012","BK0028","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620285092","title":"INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2620285092","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620285092?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:00","pubTimestamp":1773921600,"startTime":"0","endTime":"0","summary":"Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March  19, 2026  --  INmune Bio Inc.  , a clinical-stage inflammation and immunology company, today announced that Malú Gámez Tansey, Ph.D., Professor of Neurology at the Stark Neuroscience Research Institute at Indiana University School of Medicine, will feature the Company’s Phase 2 MINDFuL trial of XPro  as a centerpiece of her plenary presentation at AD/PD 2026 — the world’s leading international conference on Alzheimer’s and Parkinson’s diseases — taking place March 17–21, 2026 in Copenhagen, Denmark. Dr. Tansey is among the most respected voices in neuroimmunology, having spent her career mapping the role of peripheral inflammation in neurodegenerative disease and identifying soluble TNF as one of its most consequential drivers. Her plenary talk, titled “The Role of Peripheral Inflammation in Neurode","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3258912/0/en/INmune-Bio-s-MINDFuL-Trial-Featured-at-AD-PD-2026-Plenary-as-Successful-Example-of-How-to-Approach-Clinical-Trials-Targeting-Inflammation-in-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INMB","PD","BK4023","BK4132","AD","LU1169589451.USD","LU1169590202.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620255184","title":"Medicenna to Showcase First-in-Class Tumor-Targeted PD-1 x IL-2 Superkine at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620255184","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620255184?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:29","pubTimestamp":1773836995,"startTime":"0","endTime":"0","summary":"Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has provided an update. Medicenna Therapeutics will present updated preclinical data at the AACR Annual...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicenna-to-showcase-first-in-class-tumor-targeted-pd-1-x-il-2-superkine-at-aacr-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicenna-to-showcase-first-in-class-tumor-targeted-pd-1-x-il-2-superkine-at-aacr-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4023","LU1169589451.USD","LU1169590202.USD","PD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}